e-Drug3D

1185

EVEROLIMUS


INN
EVEROLIMUS

cas 159351-69-6
CLASS

ANTINEOPLASTIC
INHIBITOR OF SERINE-THREONINE KINASE MTOR (MAMMALIAN TARGET OF RAPAMYCIN) DOWNSTREAM OF THE PI3K/AKT PATHWAY BY BINDING TO FKBP-12
ADVANCED PANCREATIC NEUROENDOCRINE TUMORS
IMMUNOSUPPRESSANT
PROPHYLAXIS OF ORGAN REJECTION
TREATMENT OF RENAL ANGIOMYOLIPOMA ASSOCIATED WITH TUBEROUS SCLEROSIS COMPLEX AND TREATMENT OF SUBEPENDYMAL GIANT CELL ASTROCYTOMA ASSOCIATED WITH TUBEROUS SCLEROSIS COMPLEX (DRUG FOR RARE DISEASE IN EUROPE)

ROUTE (list)

ORAL

ATC code

L01EG02
L04AH02

PK parameters

VD 358 LITER
Cl 8.2 LITER / HOUR (EQN)
PPB 74 PERCENT
t1/2 30 HOUR

Solubility

POORLY SOLUBLE IN WATER


Target

TARGET FK506 BINDING PROTEIN-12 (FKBP-12)/MTOR COMPLEX

DrugCentral

Peptidyl-prolyl cis-trans isomerase FKBP1A UNIPROT P62942 FKBP1A

Download SDF file Rapamycin, 42-O-(2-hydroxyethyl)-

Formula:
C53H83NO14

Calculated chemical properties:

MW 958.20
NB_atoms 68
XLogP 6.20
PSA 171.443
NB_HD 3
NB_HA 15
fsp3 0.75
Lipinski(0=no;1=yes) 0

FDA
NDA 022334 (pdf not found) INN (EVEROLIMUS) AFINITOR (NOVARTIS) APPROVAL= AP YEAR= 2009
NDA 021560 (pdf not found) INN (EVEROLIMUS) ZORTRESS (NOVARTIS) APPROVAL= AP YEAR= 2010
NDA 203985 (pdf not found) INN (EVEROLIMUS) AFINITOR DISPERZ (NOVARTIS PHARM) APPROVAL= AP YEAR= 2012
NDA 206133 (pdf not found) INN (EVEROLIMUS) EVEROLIMUS (HIKMA) APPROVAL= AP YEAR= 2018
NDA 210130 (pdf not found) INN (EVEROLIMUS) EVEROLIMUS (MYLAN) APPROVAL= AP YEAR= 2019
NDA 207934 (pdf not found) INN (EVEROLIMUS) EVEROLIMUS (PH HEALTH) APPROVAL= AP YEAR= 2019
NDA 210050 (pdf not found) INN (EVEROLIMUS) EVEROLIMUS (TEVA PHARMS USA) APPROVAL= AP YEAR= 2019
NDA 207486 (pdf not found) INN (EVEROLIMUS) EVEROLIMUS (HIKMA) APPROVAL= AP YEAR= 2020
NDA 212936 (pdf not found) INN (EVEROLIMUS) EVEROLIMUS (MYLAN) APPROVAL= AP YEAR= 2020 DISCONTINUED
NDA 205426 (pdf not found) INN (EVEROLIMUS) EVEROLIMUS (BRECKENRIDGE) APPROVAL= AP YEAR= 2021
NDA 205432 (pdf not found) INN (EVEROLIMUS) EVEROLIMUS (BRECKENRIDGE) APPROVAL= AP YEAR= 2021
NDA 214182 (pdf not found) INN (EVEROLIMUS) EVEROLIMUS (BIOCON PHARMA) APPROVAL= AP YEAR= 2021
NDA 205775 (pdf not found) INN (EVEROLIMUS) EVEROLIMUS (PH HEALTH) APPROVAL= AP YEAR= 2021
NDA 214138 (pdf not found) INN (EVEROLIMUS) EVEROLIMUS (ALKEM LABS LTD) APPROVAL= AP YEAR= 2021
NDA 216140 (pdf not found) INN (EVEROLIMUS) EVEROLIMUS (BIOCON PHARMA) APPROVAL= AP YEAR= 2025
NDA 217640 (pdf not found) INN (EVEROLIMUS) EVEROLIMUS (NATCO) APPROVAL= AP YEAR= 2025
NDA 218863 (pdf not found) INN (EVEROLIMUS) EVEROLIMUS (AMNEAL) APPROVAL= AP YEAR= 2025

Other links:

PubChem
ChemicalProbes

U.S. repository of Clinical Trials

VigiAccess
SIDER side effects

ChemSynthesis
Patent@SureChEMBL